Lilly(Eli) & Company

NYSE: LLY
$747.46
-$0.55 (-0.1%)
Real Time Data Delayed 15 Min.

LLY Articles

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair...
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
A recent research note from SunTrust Robinson Humphrey highlights some outstanding stocks that are out of favor.
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product cycle and an attractive five-year growth rate.
A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks that may continue to show sector leadership.
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
One area that makes sense for growth investors is the large cap pharmaceuticals. Here are some the top pharmaceutical stocks to buy now according to Jefferies.
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Thursday's top analyst upgrades, downgrades include Apple, Barrick Gold, Corning, Groupon, Peabody Energy and SolarCity.
In a new research report, the SunTrust Robinson Humphrey team highlights the top pharmaceutical stocks to buy for 2015.
Thursday's top analyst upgrades and downgrades from 24/7 Wall St. include ARIAD Pharmaceuticals, FedEx, Genpact, Suncor Energy, Travelers and UPS.
ThinkstockStocks have enjoyed yet another wonderful year in 2014, and the bull market is now more than five and a half years old. With the S&P 500 index up almost 14% year-to-date ahead of...
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Thursday, July 31, 2014. They include Cliffs Natural Resources, Eli Lilly, Enphase Energy, Lululemon,...